You are here

Juno jumps on cancer therapy wave

But the journey to commercialising the bespoke medication remains daunting

Juno shot up to US$35 on Friday after its shares were priced at US$24 on Thursday to raise more than US$200 million.


IT'S a cancer therapy straight out of Greek mythology, bespoke medicine with astonishing results in the smallest and sickest of patients.

The treatment, called a chimeric antigen receptor, or CAR for short, has captured the attention of the biggest drug companies and